← SynDRA
GALANTAMINE
SynDRA canonical compound SYN0001314 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | BCHE |
| Mechanism of action | Acetylcholinesterase inhibitor |
| Indication | senile dementia |
| Disease area | neurology/psychiatry |
All known targets
- ACHE
- BCHE
- CHRNA7
- CHRNG
- CHRNE
- CHRND
- CHRNB4
- CHRNB3
- CHRNB2
- CHRNB1
- CHRNA9
- CHRNA6
Mechanisms of action (all sources)
- Acetylcholinesterase inhibitor
- ACHE INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- OPRM1
- ADORA1
- IDH1
- MC4R
- MC3R
- MAPK3
- MAPK14
- MAPK1
- MAOA
- LMNA
- LCK
- KDR
- KCNH2
- KAT2A
- HTR6
- MMP1
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- HMGCR
- HDAC6
- GSK3B
- GMNN
- FYN
- MC5R
- MMP9
- ADORA2A
- NPY1R
- VDR
- TDP1
- TBXAS1
- TBXA2R
- TACR2
- TACR1
- SLC6A4
- SLC6A3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Cholinesterase Inhibitors
- Central Nervous System Agents
- Cholinergic Agents
- Enzyme Inhibitors
- Neurotransmitter Agents
- Nootropic Agents
- Parasympathomimetics
- Peripheral Nervous System Agents
- Cholinesterase Inhibitor
ATC classes
- N06D · ANTI-DEMENTIA DRUGS
Cross-references
Synonyms
- GALANTAMINE HYDROBROMIDE
- RAZADYNE
- RAZADYNE ER
- Razadyne
- galantamin
- galantamina
- lycoremin
- lycoremine
- galanthamine
- (-)-Galantamine
- (-)-Galanthamine
- galantamine hydrobromide
- galanthamine hydrobromide
- Galantamina
- (-)-galantamine
- (-)-galanthamine
- Galanthamine
- NSC-100058
- Acumor xl
- Consion xl
- Elmino xl
- Galsya xl
- Galzemic xl
- Gatalin xl
- Gazylan xl
- Lotprosin xl
- Luventa xl
- Reminyl
- Reminyl xl
- Zeebral xl
- GNT
- Galantamin
- Galantaminum
- Galanthaminum
- Jilkon
- Lycoremin
- Lycoremine
- Razadyne ER
Reported adverse events
- Bradycardia
- Depression
- Dizziness
- Dyspepsia
- Fatigue
- Headache
- Nausea
- Somnolence
- Syncope
- Tremor
- Vomiting
- Asthenia
Look up GALANTAMINE in the interactive SynDRA portal →